The clinical impact of modified transpancreatic mattress sutures with polyglactin 910 woven mesh on postoperative pancreatic fistula in distal pancreatectomy.


Journal

Surgery
ISSN: 1532-7361
Titre abrégé: Surgery
Pays: United States
ID NLM: 0417347

Informations de publication

Date de publication:
10 2022
Historique:
received: 09 01 2022
revised: 08 05 2022
accepted: 16 05 2022
pubmed: 1 7 2022
medline: 28 9 2022
entrez: 30 6 2022
Statut: ppublish

Résumé

We previously reported the stump closure method for the remnant pancreas in distal pancreatectomy, in which soft coagulation and polyglycolic acid felt attached with fibrin glue were utilized. Transpancreatic mattress suture with polyglactin 910 woven mesh was recently reported as a novel stump closure technique. We developed the modified transpancreatic mattress suture with polyglactin 910 woven mesh method, which combined our polyglycolic acid felt method with the transpancreatic mattress suture with polyglactin 910 woven mesh method. The polyglycolic acid felt group included patients undergoing distal pancreatectomy in whom the pancreatic stump was closed with the polyglycolic acid felt method from 2017 to 2018 (n = 54); whereas the modified transpancreatic mattress suture with polyglactin 910 woven mesh group included those whose stump was closed with the modified transpancreatic mattress suture with polyglactin 910 woven mesh method from 2019 to 2020 (n = 51). Perioperative parameters, including grade B/C postoperative pancreatic fistula (clinically relevant postoperative pancreatic fistula), were assessed according to the stump closure method. The incidence of clinically relevant postoperative pancreatic fistula was significantly lower in the modified transpancreatic mattress suture with polyglactin 910 woven mesh group than in the polyglycolic acid felt group (7.8% vs 22.2%, P = .036). In multivariate analysis, the use of neoadjuvant chemoradiotherapy and the transpancreatic mattress suture with polyglactin 910 woven mesh method were independent factors for preventing clinically relevant postoperative pancreatic fistula (P = .011 and 0.0038, respectively). Moreover, in the modified transpancreatic mattress suture with polyglactin 910 woven mesh group, the incidence of clinically relevant postoperative pancreatic fistula in patients with a thick pancreas (≥13 mm, 6.7%) was comparably as low as that in patients with a thin pancreas (<13 mm, 9.5%). The modified transpancreatic mattress suture with polyglactin 910 woven mesh method is an effective stump closure technique to prevent clinically relevant postoperative pancreatic fistula after distal pancreatectomy. Our results warrant further prospective investigation to evaluate the efficacy of the modified transpancreatic mattress suture with polyglactin 910 woven mesh method compared with other standard closure methods (eg, stapler closure or hand-sewn closure).

Sections du résumé

BACKGROUND
We previously reported the stump closure method for the remnant pancreas in distal pancreatectomy, in which soft coagulation and polyglycolic acid felt attached with fibrin glue were utilized. Transpancreatic mattress suture with polyglactin 910 woven mesh was recently reported as a novel stump closure technique. We developed the modified transpancreatic mattress suture with polyglactin 910 woven mesh method, which combined our polyglycolic acid felt method with the transpancreatic mattress suture with polyglactin 910 woven mesh method.
METHODS
The polyglycolic acid felt group included patients undergoing distal pancreatectomy in whom the pancreatic stump was closed with the polyglycolic acid felt method from 2017 to 2018 (n = 54); whereas the modified transpancreatic mattress suture with polyglactin 910 woven mesh group included those whose stump was closed with the modified transpancreatic mattress suture with polyglactin 910 woven mesh method from 2019 to 2020 (n = 51). Perioperative parameters, including grade B/C postoperative pancreatic fistula (clinically relevant postoperative pancreatic fistula), were assessed according to the stump closure method.
RESULTS
The incidence of clinically relevant postoperative pancreatic fistula was significantly lower in the modified transpancreatic mattress suture with polyglactin 910 woven mesh group than in the polyglycolic acid felt group (7.8% vs 22.2%, P = .036). In multivariate analysis, the use of neoadjuvant chemoradiotherapy and the transpancreatic mattress suture with polyglactin 910 woven mesh method were independent factors for preventing clinically relevant postoperative pancreatic fistula (P = .011 and 0.0038, respectively). Moreover, in the modified transpancreatic mattress suture with polyglactin 910 woven mesh group, the incidence of clinically relevant postoperative pancreatic fistula in patients with a thick pancreas (≥13 mm, 6.7%) was comparably as low as that in patients with a thin pancreas (<13 mm, 9.5%).
CONCLUSION
The modified transpancreatic mattress suture with polyglactin 910 woven mesh method is an effective stump closure technique to prevent clinically relevant postoperative pancreatic fistula after distal pancreatectomy. Our results warrant further prospective investigation to evaluate the efficacy of the modified transpancreatic mattress suture with polyglactin 910 woven mesh method compared with other standard closure methods (eg, stapler closure or hand-sewn closure).

Identifiants

pubmed: 35773024
pii: S0039-6060(22)00363-4
doi: 10.1016/j.surg.2022.05.016
pii:
doi:

Substances chimiques

Fibrin Tissue Adhesive 0
Polyglycolic Acid 26009-03-0
Polyglactin 910 34346-01-5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1220-1227

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Hiroki Imamura (H)

Department of Surgery, Osaka International Cancer Institute, Chuo-ku, Osaka, Japan.

Hidenori Takahashi (H)

Department of Surgery, Osaka International Cancer Institute, Chuo-ku, Osaka, Japan. Electronic address: htakahashi@oici.jp.

Hirofumi Akita (H)

Department of Surgery, Osaka International Cancer Institute, Chuo-ku, Osaka, Japan.

Hiroshi Wada (H)

Department of Surgery, Osaka International Cancer Institute, Chuo-ku, Osaka, Japan.

Yosuke Mukai (Y)

Department of Surgery, Osaka International Cancer Institute, Chuo-ku, Osaka, Japan.

Kei Asukai (K)

Department of Surgery, Osaka International Cancer Institute, Chuo-ku, Osaka, Japan.

Shinichiro Hasegawa (S)

Department of Surgery, Osaka International Cancer Institute, Chuo-ku, Osaka, Japan.

Yoshiaki Fujii (Y)

Department of Surgery, Osaka International Cancer Institute, Chuo-ku, Osaka, Japan.

Takahito Sugase (T)

Department of Surgery, Osaka International Cancer Institute, Chuo-ku, Osaka, Japan.

Masaaki Yamamoto (M)

Department of Surgery, Osaka International Cancer Institute, Chuo-ku, Osaka, Japan.

Tomohira Takeoka (T)

Department of Surgery, Osaka International Cancer Institute, Chuo-ku, Osaka, Japan.

Naoki Shinno (N)

Department of Surgery, Osaka International Cancer Institute, Chuo-ku, Osaka, Japan.

Hisashi Hara (H)

Department of Surgery, Osaka International Cancer Institute, Chuo-ku, Osaka, Japan.

Takashi Kanemura (T)

Department of Surgery, Osaka International Cancer Institute, Chuo-ku, Osaka, Japan.

Naotsugu Haraguchi (N)

Department of Surgery, Osaka International Cancer Institute, Chuo-ku, Osaka, Japan.

Junichi Nishimura (J)

Department of Surgery, Osaka International Cancer Institute, Chuo-ku, Osaka, Japan.

Chu Matsuda (C)

Department of Surgery, Osaka International Cancer Institute, Chuo-ku, Osaka, Japan.

Masayoshi Yasui (M)

Department of Surgery, Osaka International Cancer Institute, Chuo-ku, Osaka, Japan.

Takeshi Omori (T)

Department of Surgery, Osaka International Cancer Institute, Chuo-ku, Osaka, Japan.

Hiroshi Miyata (H)

Department of Surgery, Osaka International Cancer Institute, Chuo-ku, Osaka, Japan.

Masayuki Ohue (M)

Department of Surgery, Osaka International Cancer Institute, Chuo-ku, Osaka, Japan.

Masato Sakon (M)

Department of Surgery, Osaka International Cancer Institute, Chuo-ku, Osaka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH